Table 2 Overview of recent treatment patterns of gout in the USA
From: Gout. Novel therapies for treatment of gout and hyperuricemia
| Total ambulatory visits, and visits to primary care versus specialists | |
| Total number of ambulatory care visits | 973 million |
| Number of visits for gout | 3.9 million (0.4% of total) |
| Percentage of total visits for gout to: | |
| Primary care | 69% |
| Cardiologists | 10% |
| 'Other specialists or unknown' | <16% |
| Rheumatologists | <2% |
| Number of gout patient-specific anti-inflammatory prescriptions (absolute number of prescriptions/year) | |
| Colchicine | ~381,000 |
| NSAIDs | ~700,000 |
| Prednisone | ~341,000 |
| Number of gout patient-specific urate-lowering prescriptions (absolute number of prescriptions/year) | |
| Allopurinol | 2.8 million |
| Probenecid | 8,000 |
| Demographics of allopurinol prescribing: percentage of gout patients that are: | |
| Caucasian | 80% |
| African Americans | 49% |
| Asians | 19% |
